Menu
← Oncology Approval Tracker
FDA DECISION ·
Lanreotide Injection
lanreotide acetate · InvaGen Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival.
LAMPGEN ANALYSIS
Why it matters
This 505(b)(2) NDA approves a lanreotide injection product for an established tumor setting.
What research teams should watch
Verify the product, syringe presentation, injection technique and neuroendocrine tumor differentiation.
PRIMARY RECORDS